Indications for Use: Vildagliptin PSK is indicated for use in type 2 diabetes mellitus in adult patients (in combination with diet therapy and exercise):

• as monotherapy in case of ineffectiveness of diet therapy and exercise in patients with contraindications to use / intolerance to metformin or in case of ineffectiveness of metformin;
• in combination with metformin as an initial drug therapy for insufficient effectiveness of diet therapy and exercise;
• as part of a two-component combination therapy: with metformin or thiazolidinedione, or with insulin in case of ineffectiveness of diet therapy, exercise and monotherapy with these drugs;
• as part of a two-component combination therapy with sulfonylureas in patients with insufficient glycemic control against the background of the maximum tolerated dose of a sulfonylurea derivative or in the presence of contraindications to the use / intolerance of metformin;
• as part of triple combination therapy: in combination with sulfonylurea derivatives and metformin, in patients who previously received therapy with sulfonylurea derivatives and metformin on the background of diet therapy and exercise and who did not achieve adequate glycemic control;
• as part of triple combination therapy: in combination with insulin and metformin, in patients who previously received stable-dose insulin and metformin on the background of diet therapy and exercise, and who did not achieve adequate glycemic control.

This product is included in the Essential Drug List (EDL).

Prescription Status: Rx only.

CONTRAINDICATIONS APPLY. PLEASE CONSULT A SPECIALIST BEFORE USE.

For the full version of the medical instruction for Vildagliptin PSK (Vildagliptin) tablets, 50 mg, please visit the open access website at https://grls.rosminzdrav.ru/Default.aspx